Hemoglobinopathies

Retina: Fourth Edition

Volumn 2-3, Issue , 2005, Pages 1429-1445

  Emerson, Geoffrey G ^a   Harlan, Joseph B ^b,c   Fekrat, Sharon ^d   Lutty, Gerard A ^a   Goldberg, Morton F ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SINAI HOSPITAL OF BALTIMORE   (United States)

^d DUKE UNIVERSITY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955068876     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-02598-0.50085-9     Document Type: Chapter

References (159)

1. Gagliano DA, Jampol L, Rabb M Sickle cell disease. Duane's clinical ophthalmology 1996, vol 3:1-40. Lippincott-Raven, Philadelphia. W.S. Tasman, E. Jaeger (Eds.).
2. Jandl J Blood. Pathophysiology 1991, Blackwell Scientific Publications, Cambridge.
3. Steinberg M Management of sickle cell disease. N Engl J Med 1999, 340:1021-1030.
4. Welch RB, Goldberg MF Sickle-cell hemoglobin and its relation to fundus abnormality. Arch Ophthalmol 1966, 75:353-362.
5. Goldberg MF Retinal neovascularization in sickle cell retinopathy. Trans Am Acad Ophthalmol Otolaryngol 1977, 83:OP409-OP431.
6. Bloch R Hematologic disorders. Clinical ophthalmology 1994, 5. Harper & Row, Philadelphia, . T. Duane, E. Jaeger (Eds.).
7. Nia J, Lam WC, Kleinman DM, et al. Retinopathy in sickle cell trait: does it exist?. Can J Ophthalmol 2003, 38:46-51.
8. Mehta JS, Whittaker KW, Tsaloumas MD Latent proliferative sickle cell retinopathy in sickle cell trait. Acta Ophthalmol Scand 2001, 79:81-82.
9. Serjeant G Sickle cell disease 1985, Oxford University Press, Oxford.
10. Goldberg MF Sickled erythrocytes, hyphema, and secondary glaucoma: I. The diagnosis and treatment of sickled erythrocytes in human hyphemas. Ophthalm Surg 1979, 10:17-31.
11. Herrick J Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med 1910, 6:517-621.
12. Bunn HF Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997, 337:762-769.
13. Mozzarelli A, Hofrichter J, Eaton WA Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. Science 1987, 237:500-506.
14. Kaul DK, Fabry ME, Nagel RL The pathophysiology of vascular obstruction in the sickle syndromes. Blood Rev 1996, 10:29-44.
15. Fabry ME, Nagel RL Heterogeneity of red cells in the sickler: a characteristic with practical clinical and pathophysiological implications. Blood Cells 1982, 8:9-15.
16. Kaul DK, Fabry ME, Windisch P, et al. Erythrocytes in sickle cell anemia are heterogeneous in their rheological and hemodynamic characteristics. J Clin Invest 1983, 72:22-31.
17. Brugnara C, Gee B, Armsby CC, et al. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1996, 97:1227-1234.
18. Brugnara C, Kopin AS, Bunn HF, et al. Regulation of cation content and cell volume in hemoglobin erythrocytes from patients with homozygous hemoglobin C disease. J Clin Invest 1985, 75:1608-1617.
19. Canessa M, Spalvins A, Nagel RL Volume-dependent and NEM-stimulated K+,Cl- transport is elevated in oxygenated SS, SC and CC human red cells. FEBS Lett 1986, 200:197-202.
20. Fabry ME, Romero JR, Buchanan ID, et al. Rapid increase in red blood cell density driven by K:Cl cotransport in a subset of sickle cell anemia reticulocytes and discocytes. Blood 1991, 78:217-225.
21. Mathews M, McLeod DS, Merges C, et al. Neutrophils and leucocyte adhesion molecules in sickle cell retinopathy. Br J Ophthalmol 2002, 86:684-690.
22. Joneckis CC, Ackley RL, Orringer EP, et al. Integrin alpha 4 beta 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood 1993, 82:3548-3555.
23. Setty BN, Stuart MJ Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. Blood 1996, 88:2311-2320.
24. Swerlick RA, Eckman JR, Kumar A, et al. Alpha 4 beta 1-integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium. Blood 1993, 82:1891-1899.
25. Lutty GA, Otsuji T, Taomoto M, et al. Mechanisms for sickle red blood cell retention in choroid. Curr Eye Res 2002, 25:163-171.
26. Solovey A, Lin Y, Browne P, et al. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997, 337:1584-1590.
27. Francis RB, Haywood LJ Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. J Natl Med Assoc 1992, 84:611-615.
28. Francis RB Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis 1989, 19:105-111.
29. Kunz M, Cao J, Merges C, et al. Adhesion molecules, neutrophils and imbalance in the fibrinolytic system in sickle cell retinopathy. Invest Ophthalmol Vis Sci 1997, 38(suppl):1117.
30. Lutty GA, Merges C, Crone S, et al. Immunohistochemical insights into sickle cell retinopathy. Curr Eye Res 1994, 13:125-138.
31. Horne MK Sickle cell anemia as a rheologic disease. Am J Med 1981, 70:288-298.
32. Lutty GA, Phelan A, McLeod DS, et al. A rat model for sickle cell-mediated vaso-occlusion in retina. Microvasc Res 1996, 52:270-280.
33. Paton D The conjunctival sign of sickle-cell disease. Arch Ophthalmol 1961, 66:90-94.
34. Fink AI, Funahashi T, Robinson M, et al. Conjunctival blood flow in sickle-cell disease. Preliminary report. Arch Ophthalmol 1961, 66:824-829.
35. Paton D The conjunctival sign of sickle-cell disease. Further observations. Arch Ophthalmol 1962, 68:627-632.
36. Nagpal KC, Goldberg MF, Rabb MF Ocular manifestations of sickle hemoglobinopathies. Surv Ophthalmol 1977, 21:391-411.
37. Funahashi T, Fink A, Robinson M, et al. Pathology of conjunctival vessels in sickle-cell disease. A preliminary report. Am J Ophthalmol 1964, 57:713-718.
38. Nagpal KC, Asdourian GK, Goldbaum MH, et al. The conjunctival sickling sign, hemoglobin S, and irreversibly sickled erythrocytes. Arch Ophthalmol 1977, 95:808-811.
39. Chambers J, Puglisi J, Kernitsky R, et al. Iris atrophy in hemoglobin SC disease. Am J Ophthalmol 1974, 77:247-249.
40. Galinos S, Rabb MF, Goldberg MF, et al. Hemoglobin SC disease and iris atrophy. Am J Ophthalmol 1973, 75:421-425.
41. Romayanada N, Goldberg MF, Green WR Histopathology of sickle cell retinopathy. Trans Am Acad Ophthalmol Otolaryngol 1973, 77:OP642-OP676.
42. Gagliano DA, Goldberg MF The evolution of salmon-patch hemorrhages in sickle cell retinopathy. Arch Ophthalmol 1989, 107:1814-1815.
43. Condon PI, Serjeant GR Ocular findings in hemoglobin SC disease in Jamaica. Am J Ophthalmol 1972, 74:921-931.
44. Condon PI, Serjeant GR Ocular findings in homozygous sickle cell anemia in Jamaica. Am J Ophthalmol 1972, 73:533-543.
45. Condon PI, Serjeant GR Ocular findings in sickle cell thalassemia in Jamaica. Am J Ophthalmol 1972, 74:1105-1109.
46. Goldberg MF Natural history of untreated proliferative sickle retinopathy. Arch Ophthalmol 1971, 85:428-437.
47. Levine RA, Kaplan AM The ophthalmoscopic findings in C + S disease. Am J Ophthalmol 1965, 59:37-42.
48. van Meurs JC Evolution of a retinal hemorrhage in a patient with sickle cell-hemoglobin C disease. Arch Ophthalmol 1995, 113:1074-1075.
49. Asdourian G, Nagpal KC, Goldbaum M, et al. Evolution of the retinal black sunburst in sickling haemoglobinopathies. Br J Ophthalmol 1975, 59:710-716.
50. Liang JC, Jampol LM Spontaneous peripheral chorioretinal neovascularisation in association with sickle cell anaemia. Br J Ophthalmol 1983, 67:107-110.
51. Lutty GA, McLeod DS, Pachnis A, et al. Retinal and choroidal neovascularization in a transgenic mouse model of sickle cell disease. Am J Pathol 1994, 145:490-497.
52. Cogan DG Ophthalmic manifestations of systemic vascular disease. Major Probl Intern Med 1974, 3:1-187.
53. Wise G, Dollery C, Henkind P The retinal circulation 1971, Harper & Row, New York.
54. Asdourian GK, Nagpal KC, Busse B, et al. Macular and perimacular vascular remodelling sickling haemoglobinopathies. Br J Ophthalmol 1976, 60:431-453.
55. Acacio I, Goldberg MF Peripapillary and macular vessel occlusions in sickle cell anemia. Am J Ophthalmol 1973, 75:861-866.
56. Conrad WC, Penner R Sickle-cell trait and central retinal-artery occlusion. Am J Ophthalmol 1967, 63:465-468.
57. Goodman G, Von Sallmann L, Holland MG Ocular manifestations of sickle-cell disease. Arch Opthalmol 1957, 58:655-682.
58. Kabakow B, Van Weimokly SS, Lyons HA Bilateral central retinal artery occlusion; occurrence in a patient with cortisone-treated systemic lupus erythematosus, sickle cell trait, and active pulmonary tuberculosis. Arch Opthalmol 1955, 54:670-676.
59. Klein ML, Jampol LM, Condon PI, et al. Central retinal artery occlusion without retrobulbar hemorrhage after retrobulbar anesthesia. Am J Ophthalmol 1982, 93:573-577.
60. Knapp JW Isolated macular infarction in sickle cell (SS) disease. Am J Ophthalmol 1972, 73:857-859.
61. Lieb W, Geeraets W, Guerry D Ocular and systemic manifestions of sickle cell disease. Acta Ophthalmol 1951, 58:25-45.
62. Ryan SJ Occlusion of the macular capillaries in sickle cell hemoglobin C disease. Am J Ophthalmol 1974, 77:459-461.
63. Weissman H, Nadel AJ, Dunn M Simultaneous bilateral retinal arterial occlusions treated by exchange transfusions. Arch Ophthalmol 1979, 97:2151-2153.
64. Appen RE, Wray SH, Cogan DG Central retinal artery occlusion. Am J Ophthalmol 1975, 79:374-381.
65. Chopdar A Multiple major retinal vascular occlusions in sickle cell haemoglobin C disease. Br J Ophthalmol 1975, 59:493-496.
66. Condon PI, Whitelocke RA, Bird AC, et al. Recurrent visual loss in homozygous sickle cell disease. Br J Ophthalmol 1985, 69:700-706.
67. McLeod DS, Goldberg MF, Lutty GA Dual-perspective analysis of vascular formations in sickle cell retinopathy. Arch Ophthalmol 1993, 111:1234-1245.
68. Goldbaum MH Retinal depression sign indicating a small retinal infarct. Am J Ophthalmol 1978, 86:45-55.
69. Roy MS, Gascon P, Giuliani D Macular blood flow velocity in sickle cell disease: relation to red cell density. Br J Ophthalmol 1995, 79:742-745.
70. Stevens TS, Busse B, Lee CB, et al. Sickling hemoglobinopathies; macular and perimacular vascular abnormalities. Arch Ophthalmol 1974, 92:455-463.
71. Marsh RJ, Ford SM, Rabb MF, et al. Macular vasculature, visual acuity, and irreversibly sickled cells in homozygous sickle cell disease. Br J Ophthalmol 1982, 66:155-160.
72. Goldberg MF Retinal vaso-occlusion in sickling hemoglobinopathies. Birth Defects Orig Artic Ser 1976, 12:475-515.
73. Condon PI, Serjeant GR, Ikeda H Unusual chorioretinal degeneration in sickle cell disease. Possible sequelae of posterior ciliary vessel occlusion. Br J Ophthalmol 1973, 57:81-88.
74. Dizon RV, Jampol LM, Goldberg MF, et al. Choroidal occlusive disease in sickle cell hemoglobinopathies. Surv Ophthalmol 1979, 23:297-306.
75. Stein MR, Gay AJ Acute chorioretinal infarction in sickle cell trait. Report of a case. Arch Ophthalmol 1970, 84:485-490.
76. Ryan SJ, Goldberg MF Anterior segment ischemia following scleral buckling in sickle cell hemoglobinopathy. Am J Ophthalmol 1971, 72:35-50.
77. Condon PI, Serjeant GR The progression of sickle cell eye disease in Jamaica. Doc Ophthalmol 1975, 39:203-210.
78. Nagpal KC, Huamonte F, Constantaras A, et al. Migratory white-without-pressure retinal lesions. Arch Ophthalmol 1976, 94:576-579.
79. Nagpal KC, Goldberg MF, Asdourian G, et al. Dark-without-pressure fundus lesions. Br J Ophthalmol 1975, 59:476-479.
80. Condon PI, Sergeant GR Behaviour of untreated proliferative sickle retinopathy. Br J Ophthalmol 1980, 64:404-411.
81. Kimmel AS, Magargal LE, Tasman WS Proliferative sickle retinopathy and neovascularization of the disc: regression following treatment with peripheral retinal scatter laser photocoagulation. Ophthalm Surg 1986, 17:20-22.
82. Ober RR, Michels RG Optic disk neovascularization in hemoglobin SC disease. Am J Ophthalmol 1978, 85:711-714.
83. Raichand M, Goldberg MF, Nagpal KC, et al. Evolution of neovascularization in sickle cell retinopathy. A prospective fluorescein angiographic study. Arch Ophthalmol 1977, 95:1543-1552.
84. Clarkson JG The ocular manifestations of sickle-cell disease: a prevalence and natural history study. Trans Am Ophthalmol Soc 1992, 90:481-504.
85. Nagpal K Angioid streaks and sickle hemoglobinopathies. Br J Ophthalmol 1977, 37:325-328.
86. Jampol LM, Green JL, Goldberg MF, et al. An update on vitrectomy surgery and retinal detachment repair in sickle cell disease. Arch Ophthalmol 1982, 100:591-593.
87. Goldberg MF Classification and pathogenesis of proliferative sickle retinopathy. Am J Ophthalmol 1971, 71:649-665.
88. Cao J, Mathews MK, McLeod DS, et al. Angiogenic factors in human proliferative sickle cell retinopathy. Br J Ophthalmol 1999, 83:838-846.
89. Cao J, Kunz M, Merges C, et al. Immunolocalization of angiogenic factors in proliferative sickle cell retinopathy. Invest Ophthalmol Vis Sci 1997, 38(suppl.):1117.
90. Lutty GA, McLeod DS, Merges C, et al. Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthalmol 1996, 114:971-977.
91. Curtis AS, Seehar GM The control of cell division by tension or diffusion. Nature 1978, 274:52-53.
92. McLeod DS, Merges C, Fukushima A, et al. Histopathologic features of neovascularization in sickle cell retinopathy. Am J Ophthalmol 1997, 124:455-472.
93. Condon P, Jampol LM, Farber MD, et al. A randomized clinical trial of feeder vessel photocoagulation of proliferative sickle cell retinopathy. II. Update and analysis of risk factors. Ophthalmology 1984, 91:1496-1498.
94. Isbey H, Clifford G, Tanaka K Vitreous hemorrhage associated with sickle-cell trait and sickle-cell hemoglobin C disease. Am J Ophthalmol 1958, 45:870-879.
95. Kearney WF Sickle cell ophthalmopathy. NY State J Med 1965, 65:2677-2681.
96. Farber MD, Jampol LM, Fox P, et al. A randomized clinical trial of scatter photocoagulation of proliferative sickle cell retinopathy. Arch Ophthalmol 1991, 109:363-367.
97. Goldberg MF, Jampol LM Treatment of neovascularization, vitreous hemorrhage, and retinal detachment in sickle cell retinopathy. Trans New Orleans Acad Ophthalmol 1983, 31:53-81.
98. Nagpal KC, Patrianakos D, Asdourian GK, et al. Spontaneous regression (autoinfarction) of proliferative sickle retinopathy. Am J Ophthalmol 1975, 80:885-892.
99. Jampol LM, Goldbaum MH Peripheral proliferative retinopathies. Surv Ophthalmol 1980, 25:1-14.
100. Kim SY, Mocanu C, McLeod DS, et al. Expression of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in sickle cell retina and choroid. Exp Eye Res 2003, 77:433-445.
101. Gitter KA, Rothschild H, Waltman DD, et al. Dominantly inherited peripheral retinal neovascularization. Arch Ophthalmol 1978, 96:1601-1605.
102. Cohen SB, Fletcher ME, Goldberg MF, et al. Diagnosis and management of ocular complications of sickle hemoglobinopathies: Part IV. Ophthalm Surg 1986, 17:312-315.
103. Goldbaum MH, Peyman GA, Nagpal KC, et al. Vitrectomy in sickling retinopathy: report of five cases. Ophthalm Surg 1976, 7:92-102.
104. Jacobson MS, Gagliano DA, Cohen SB, et al. A randomized clinical trial of feeder vessel photocoagulation of sickle cell retinopathy. A long-term follow-up. Ophthalmology 1991, 98:581-585.
105. Jampol LM, Farber M, Rabb MF, et al. An update on techniques of photocoagulation treatment of proliferative sickle cell retinopathy. Eye 1991, 5:260-263.
106. Carney MD, Paylor RR, Cunha-Vaz JG, et al. Iatrogenic choroidal neovascularization in sickle cell retinopathy. Ophthalmology 1986, 93:1163-1168.
107. Condon PI, Sergeant GR Choroid neovascularization. An important complication of photocoagulation for proliferative sickle cell retinopathy. Trans Ophthalmol Soc UK 1981, 101:429.
108. Condon PI, Jampol LM, Ford SM, et al. Choroidal neovascularisation induced by photocoagulation in sickle cell disease. Br J Ophthalmol 1981, 65:192-197.
109. Dizon-Moore RV, Jampol LM, Goldberg MF Chorioretinal and choriovitreal neovascularization. Their presence after photocoagulation of proliferative sickle cell retinopathy. Arch Ophthalmol 1981, 99:842-849.
110. Fox PD, Acheson RW, Serjeant GR Outcome of iatrogenic choroidal neovascularisation in sickle cell disease. Br J Ophthalmol 1990, 74:417-420.
111. Galinos SO, Asdourian GK, Woolf MB, et al. Choroido-vitreal neovascularization after argon laser photocoagulation. Arch Ophthalmol 1975, 93:524-530.
112. Goldbaum MH, Galinos SO, Apple D, et al. Acute choroidal ischemia as a complication of photocoagulation. Arch Ophthalmol 1976, 94:1025-1035.
113. Rednam KR, Jampol LM, Goldberg MF Scatter retinal photocoagulation for proliferative sickle cell retinopathy. Am J Ophthalmol 1982, 93:594-599.
114. Hanscom TA Indirect treatment of peripheral retinal neovascularization. Am J Ophthalmol 1982, 93:88-91.
115. Lee CB, Woolf MB, Galinos SO, et al. Cryotherapy of proliferative sickle retinopathy. Part I. Single freeze-thaw cycle. Ann Ophthalmol 1975, 7:1299-1308.
116. Fox PD, Vessey SJ, Forshaw ML, et al. Influence of genotype on the natural history of untreated proliferative sickle retinopathy - an angiographic study. Br J Ophthalmol 1991, 75:229-231.
117. Goldbaum MH, Fletcher RC, Jampol LM, et al. Cryotherapy of proliferative sickle retinopathy, II: triple freeze-thaw cycle. Br J Ophthalmol 1979, 63:97-101.
118. Aron-Rosa D, Greenspan DA Neodymium:YAG laser vitreolysis. Int Ophthalmol Clin 1985, 25:125-134.
119. Brown GC, Benson WE Treatment of diabetic traction retinal detachment with the pulsed neodymium-YAG laser. Am J Ophthalmol 1985, 99:258-262.
120. Fankhauser F, Kwasniewska S, van der Zypen E Vitreolysis with the Q-switched laser. Arch Ophthalmol 1985, 103:1166-1171.
121. Hrisomalos NF, Jampol LM, Moriarty BJ, et al. Neodymium-YAG laser vitreolysis in sickle cell retinopathy. Arch Ophthalmol 1987, 105:1087-1091.
122. Leen JS, Ratnakaram R, Del Priore LV, et al. Anterior segment ischemia after vitrectomy in sickle cell disease. Retina 2002, 22:216-219.
123. Ryan SJ Role of the vitreous in the haemoglobinopathies. Trans Ophthalmol Soc UK 1975, 95:403-406.
124. Goldberg MF Treatment of proliferative sickle retinopathy. Trans Am Acad Ophthalmol Otolaryngol 1971, 75:532-556.
125. 2. Ophthalm Surg 1979, 10:78-88.
126. Al-Abdulla NA, Haddock TA, Kerrison JB, et al. Sickle cell disease presenting with extensive peri-macular arteriolar occlusions in a nine-year-old boy. Am J Ophthalmol 2001, 131:275-276.
127. Goldberg MF The diagnosis and treatment of secondary glaucoma after hyphema in sickle cell patients. Am J Ophthalmol 1979, 87:43-49.
128. Goldberg MF The diagnosis and treatment of sickled erythrocytes in human hyphemas. Trans Am Ophthalmol Soc 1978, 76:481-501.
129. Cohen SB, Fletcher ME, Goldberg MF, et al. Diagnosis and management of ocular complications of sickle hemoglobinopathies: part V. Ophthalm Surg 1986, 17:369-374.
130. Brazier DJ, Gregor ZJ, Blach RK, et al. Retinal detachment in patients with proliferative sickle cell retinopathy. Trans Ophthalmol Soc UK 1986, 105:100-105.
131. Freilich DB, Seelenfreund MH Long-term follow-up of scleral buckling procedures with sickle cell disease and retinal detachment treated with the use of hyperbaric oxygen. Mod Probl Ophthalmol 1977, 18:368-372.
132. Rahi AH, Hungerford JL, Ahmed AI Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings. Br J Ophthalmol 1986, 70:373-381.
133. Orton RB, de Veber LL, Sulh HM Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy. Can J Ophthalmol 1985, 20:153-156.
134. Bloomfield SE, Markenson AL, Miller DR, et al. Lens opacities in thalassemia. J Pediatr Ophthalmol Strabismus 1978, 15:154-156.
135. Haimovici R, D'Amico DJ, Gragoudas ES, et al. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology 2002, 109:164-171.
136. Lakhanpal V, Schocket SS, Jiji R Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology 1984, 91:443-451.
137. Dennerlein JA, Lang GE, Stahnke K, et al. [Ocular findings in Desferal therapy]. Ophthalmologe 1995, 92:38-42.
138. Lubin BH Sickle cell disease and the endothelium. N Engl J Med 1997, 337:1623-1625.
139. Malave I, Perdomo Y, Escalona E, et al. Levels of tumor necrosis factor alpha/cachectin (TNF alpha) in sera from patients with sickle cell disease. Acta Haematol 1993, 90:172-176.
140. Moore CM, Ehlayel M, Leiva LE, et al. New concepts in the immunology of sickle cell disease. Ann Allergy Asthma Immunol 1996, 76:385-400. quiz 403.
141. Spaide RF. Personal communication.
142. Auerbach W, Auerbach R Angiogenesis inhibition: a review. Pharmacol Ther 1994, 63:265-311.
143. Fan TP, Jaggar R, Bicknell R Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 1995, 16:57-66.
144. Charache S Eye disease in sickling disorders. Hematol Oncol Clin North Am 1996, 10:1357-1362.
145. Charache S Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Semin Hematol 1997, 34(suppl. 3):15-21.
146. Ohene-Frempong K, Smith-Whitley K Use of hydroxyurea in children with sickle cell disease: what comes next?. Semin Hematol 1997, 34(suppl. 3):30-41.
147. Rogers ZR Hydroxyurea therapy for diverse pediatric populations with sickle cell disease. Semin Hematol 1997, 34(suppl. 3):42-47.
148. Constantoulakis P, Knitter G, Stamatoyannopoulos G On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC. Blood 1989, 74:1963-1971.
149. Faller DV, Perrine SP Butyrate in the treatment of sickle cell disease and beta-thalassemia. Curr Opin Hematol 1995, 2:109-117.
150. Stamatoyannopoulos G, Blau CA, Nakamoto B, et al. Fetal hemoglobin induction by acetate, a product of butyrate catabolism. Blood 1994, 84:3198-3204.
151. Liakopoulou E, Blau CA, Li Q, et al. Stimulation of fetal hemoglobin production by short chain fatty acids. Blood 1995, 86:3227-3235.
152. Adragna NC, Fonseca P, Lauf PK Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells. Blood 1994, 83:553-560.
153. Bridges KR, Barabino GD, Brugnara C, et al. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood 1996, 88:4701-4710.
154. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995, 332:1317-1322.
155. Platt OS, Guinan EC Bone marrow transplantation in sickle cell anemia - the dilemma of choice. N Engl J Med 1996, 335:426-428.
156. Vermylen C, Cornu G Bone marrow transplantation for sickle cell anemia. Curr Opin Hematol 1996, 32:163-166.
157. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996, 335(6):369-376.
158. Kaul DK, Tsai HM, Liu XD, et al. Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood 2000, 95:368-374.
159. Hebbel RP Blockade of adhesion of sickle cells to endothelium by monoclonal antibodies. N Engl J Med 2000, 342:1910-1912.